BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO – Siliconrepublic.com

We visited theBT Young Scientist and Technology Exhibition again this year, getting the chance to chat to some of the countrys brightest students.

There were project posters stretching to all corners of the main hall at the RDS, filled with excited participants waiting for their visit from the judging panel.

Hugh Murtagh from Coliste Mhuire in Westmeath took us through hisA-Ok project a discreet wristband that students with autism can wear to let their teacher know if theyre feeling overwhelmed at school.

I have autism and I know just how hard it is to try and focus in class when you feel overwhelmed. I want to try and help people like me and people who also have autism, he said.

We also learned about an eco-powered dollhouse with the potential to teach children about climate action, how mental health can be impacted by climate change, and whether genetics affects how clever a dog breed is.

>> READ MORE

Words by Lisa Ardill

See the article here:
BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO - Siliconrepublic.com

JPM: How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says – FiercePharma

SAN FRANCISCOWhen Amgen shelled out $13.4 billion late last year to pick up Celgene's blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel in its commercial tank. Now, Amgen is looking to rev up sales with new indications and launches in new international markets.

Although scant on details, Amgen CEO Bob Bradway forecast Tuesdaythat Amgen could squeeze more out of Otezla in the coming yearsafter the drug hit $547 million in sales in the third quarterassuming Amgen can follow its own mantra and execute.

"In biopharma, the focus is on innovation, innovation, innovation, and Amgen is execution, execution, execution," Bradway told investors at the annual J.P. Morgan Healthcare Conference in San Francisco.

Artificial Intelligence in the Pharma Industry

How far has the adoption of AI technology come in Life Sciences? Share your thoughts in this brief, 8-minute survey. Let your voice be heard.

In Bradway's telling, Otezla helped Amgen flesh out its immunology portfolio as a counterpart to stalwart Enbrel.

"We think the stars really aligned for us in 2019 when we were able to acquire Otezla," Bradway said. "Otezla is a great medicine, it has great valuefor us, and it came at a great time."

RELATED:Amgen, maker of Enbrel, to pick up Celgene's Otezla for $13.4B. Will FTC hit back?

Amgen picked up Otezla in a$13.4 billion deal with Celgene in August as the latter worked to secure its$74 billion merger with Bristol-Myers Squibb.

Bristol was forced to sell Otezla to win the Federal Trade Commission's clearance simply because it overlappedwith BMS own investigational TYK-2 inhibitor, BMS-986165. Despite Amgen's blockbuster Enbrel operating in the same market, the deal passed muster.

At the time, Amgen expected Otezla could enjoy at least low double-digit sales growth on average over the next five years. The Streets consensus currently has it reaching $2.5 billion in peak sales before presumably going off patent in the U.S. in 2028. At that rate,Amgen will at least be able to get its investment back in full by around 2024.

Looking ahead, Amgen expects phase 3 data for Otezla in mild to moderate psoriasis will read out this year, and the drugmaker hopes to launch the drug beyond the30-oddinternational markets where it's currently approved, Bradway said.

Excerpt from:
JPM: How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says - FiercePharma

Why There’s No Such Thing as a Truly Hypoallergenic Dog – Healthline

If you become congested and start to sneeze anytime youre near a dog, youre not alone. The American College of Allergy, Asthma, and Immunology (ACAAI) reports that almost 10 million people are allergic to their pets.

For many pet owners, buying a hypoallergenic dog sounds like the perfect solution. No more allergy pills or shots and you can still have a cute, furry friend. It sounds perfect, right?

However, when Healthline asked several allergy experts about hypoallergenic dogs, they all gave us a very emphatic no.

Theres no such thing as a truly hypoallergenic dog.

However, there are many options to consider that may allow you to own a dog without triggering a reaction if youre a person living with pet allergies.

According to allergist Dr. Tania Elliott, a spokesperson for the ACAAI, people can develop allergic reactions to pet dander (similar to dandruff in humans), saliva, urine, and hair.

When exposed to these substances, our body can mistakenly see certain proteins within them, called allergens, as a threat. To protect us, our body develops antibodies against those proteins.

When were exposed to those proteins again, we then have an allergic response. Our immune system will be activated, causing the release of histamine.

Histamine causes symptoms, such as sneezing and increased mucus production, which protect us from the invading protein.

These symptoms are what cause the discomfort we associate with an allergy.

In the case of a dog allergy, Elliott says you could develop symptoms such as itchy eyes, runny nose, asthma attacks, sneezing, and/or congestion.

You might also develop hives if youve been touched or licked by a dog.

According to Dr. Jill A. Poole, professor, division chief of allergy and immunology at the department of medicine at the University of Nebraska Medical Center, theres no such thing as a hypoallergenic dog because all dogs produce the same proteins.

Its those proteins to which youre reacting. Thats why even a so-called hypoallergenic dog can still trigger an allergic reaction.

It would be more appropriate, Poole said, to call these shedding versus non-shedding dogs.

Shedding dogs release more dog hair into their environment, leading to a buildup of dog hair in your home.

Non-shedding dogs tend to not shed their hair as easily. They must be regularly groomed to prevent matting.

When dogs shed, some people can develop an irritant response to the hair.

While the symptoms can be the same, an irritant response is different from an allergic response. Irritation doesnt trigger the production of antibodies the way an allergy does.

If you experience an irritant response to dog hair, having a dog that sheds less would reduce this.

Being vigilant about keeping loose dog hair cleaned up would also help those who are experiencing an irritant response, says Poole.

Poole says your first step in getting tested for a dog allergy would be to talk with a doctor or allergist about your symptoms and medical history. If these indicate a possible dog allergy, they can order a test for you.

This testing would be either a skin test or a blood test.

Skin and blood tests are similar in that they can detect the antibodies in your skin and blood that trigger an immune response to a particular allergen.

In a skin test, a small amount of a diluted allergen is placed under your skin, either by pricking the skin or by injection.

If you develop a red, itchy bump, called a wheal, within about 15 minutes, youre considered to be allergic to that particular allergen.

A blood test would involve drawing blood and testing it in a laboratory for the presence of antibodies.

While theres no such thing as a hypoallergenic dog, it appears that some people with dog allergies may not be allergic to all dogs.

Theres recent research indicating that people who are allergic to a specific dog protein called Can f 5 might only react to intact male dogs.

Poole explains this means that some people with dog allergies could potentially own either a female or a neutered male dog and wouldnt have an allergic reaction.

There are six different proteins that have been been identified as causing allergies in dogs: Can f 1 to 6.

Can f 5 is only produced in the prostate gland of the male.

Because of this fact, a female dog wouldnt produce an allergic reaction in people who are allergic to only this one allergen.

A neutered male produces less of this protein and might also be a safe choice.

About 30 percent of people with dog allergies are allergic to only the Can f 5 protein, Poole says.

Dr. Princess Ogbogu, director of allergy and immunology at Ohio State University Wexner Medical Center, does caution that its a bit premature to make this a standard clinical recommendation.

It is a hypothesis and not well established yet, Ogbogu said.

However, if youd like to explore this avenue further, you can speak with your doctor about testing.

A test for allergy to the Can f proteins was approved by the Food and Drug Administration in May 2019.

Poole says its important that youre tested for all of the Can f allergens and not just Can f 5. You could be allergic to more than one of them.

If youre not one of the lucky few who are only allergic to Can f 5, there are several other steps you can take that may allow you to have a canine in your home.

Poole suggests the first place to start is to try limiting your exposure to the offending allergens through environmental controls.

According to the ACAAI, environmental controls could include such things as:

Another step you can take is to use medications to manage your allergy symptoms.

Your allergist can recommend which medications will be best for you, depending on your individual symptoms.

Medications your doctor might prescribe include:

Finally, although it can be time-consuming, immunotherapy does offer more of a permanent solution to dog allergies.

Poole explains it takes about 3 to 5 years to desensitize a person to an allergen.

The protocol involves giving the person a gradually increasing dose of the allergen once or twice a week until they reach a maintenance dose.

At this point, theyd then need an injection every 2 to 4 weeks over the course of about 3 to 5 years.

Each injection is given subcutaneously (in the fat layer between the skin and muscle).

The person is then observed by a medical professional for 30 minutes in case they have an adverse reaction to the allergen.

Immunotherapy can greatly reduce, or even completely eliminate, your allergy symptoms.

Many people who love dogs are unfortunately allergic to them.

While a hypoallergenic dog might seem like a good solution, allergy experts say theres really no such thing as a hypoallergenic dog.

However, this doesnt mean youre without options. There are ways to reduce or eliminate your exposure to dog allergens. You can also take medications that manage your symptoms or have immunotherapy to desensitize you to dog allergens.

An allergist can help you learn more about your options.

Read more here:
Why There's No Such Thing as a Truly Hypoallergenic Dog - Healthline

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain – Alzforum

14 Jan 2020

As if the neurodegenerative brain didnt have enough troubles, a study published in Nature on January 8 reports that it may be swarming with highly trained cellular henchmen. Researchers led by Tony Wyss-Coray at Stanford University found cytotoxic CD8+ T cells in the cerebrospinal fluid and brain tissue of people with Alzheimers and Parkinsons disease. Far from merely surveying the brain, they had multipliedclonally expanded, in immunology parlancesuggesting they were fighting specific antigens. To what were they responding? For most of the clones, this remains a mystery. However, a small proportion of T cells in three AD patients recognized a snippet of Epstein-Barr virus, a herpesvirus known to infect cells of the CNS.

This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans, wrote Jonathan Kipnis of University of Virginia in Charlottesville. These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing, he added.

Neuroinflammation has moved to center stage in neurodegenerative disease research, but most work focuses on the innate, rather than adaptive, immune system. Still, evidence implicating the adaptive immune system has been quietly trickling in over the years. For example, scientists detected T cells specific for A and -synuclein in the blood of AD and PD patients, respectively (Bongioanni et al., 1997; Monsonego et al., 2003; Jun 2017 news).While dogma holds that T cells are scarce in the brain, a recently discovered lymphatic drainage system there carries T cells, making it clear that adaptive immune cells can, and do, frequent the CNS (Louveau et al., 2015; Oct 2017 news; Oct 2019 news). Some studies detected more T cells in the brains of people with neurodegenerative disease than in healthy brains (Togo et al., 2002; Town et al., 2005; Sept 2009 news).

In the new study, first author David Gate and colleagues set out to clarify what the adaptive immune system might do in Alzheimers. First, they took stock of immune cell populations in the blood, reporting that people with MCI or AD had more of a subtype of CD8+ T cells than did cognitively unimpaired controls. Specifically, high numbers of a subset of T effector memory cells expressing CD45RA, turned up in AD and MCI. Also known as T-EMRA cells, they are renowned for their killing efficiency, Gate told Alzforum. They rapidly dispense with any cells they recognize and also secrete a slew of proinflammatory cytokines.

In a separate cohort, the researchers found that the more circulating T-EMRA cells a person with AD or MCI had, the worse he or she performed on cognitive tests. Numbers of circulating T-EMRA cells predicted MCI or AD with 80 percent accuracy, suggesting that this particular subset of T cells in the blood was somehow tied to the neurodegenerative process in the brain.

Infiltrating the AD Brain. CD8+ T cells (green) congregate in blood vessels laden with cerebral amyloid angiopathy, and around Aplaques (red). [Courtesy of Gate et al., Nature, 2020.]

Could these cells also be in the brain, then? Immunohistochemistry on postmortem brain samples identified more CD8+ T cells in hippocampal parenchyma and adjacent leptomeninges of seven AD patients than of seven controls. The cells congregated around A plaques and neuronal processes. Gate also found numerous CD8+ T cells associated with the blood vessels affected by cerebral amyloid angiopathy in three AD patients, but found nary a T cell around the vasculature of controls. Gate did not measure other markers to determine whether these were T-EMRA cells.

Caught in the Act? A CD8+ T cell (red) in the hippocampus of an AD brain contains cytotoxic granules loaded with Granzyme A, a protein that kills target cells. [Courtesy of Gate et al., Nature, 2020.]

Gate spotted adaptive immune cells in the CSF as well. Most were T cells, but he was surprised to find 20 percent were CD8+, and of those, again 20 percent were T-EMRA. Were they just passing through, or carrying out an immunological hit? To find out, the researchers sequenced T cell receptor genes of individual T cells, which are unique due to the recombination that generates the TCRs. The existence of even two cells with identical receptor sequence indicates clonal expansion, and this occurs only when the killers encounter their cognate antigen (aka prey).

The scientists report evidence of numerous expanded clones in the CSF of 12 people with either MCI or AD (see image below). Clonal expansion was far less common among 10 controls. While one out of 10 healthy controls had a highly expanded clonei.e., one that comprised at least 3 percent of all TCR sequencesfour of six AD patients and one of five people with MCI did.

Moreover, individual clones detected in AD CSF had expanded to a greater degree than those from controls. One AD patient had a CD8+ T cell clone that comprised a whopping 44 percent of all CD8+ T cells in their CSF. Roughly two-thirds of all expanded CD8+ T cell clones belonged to the T-EMRA subset; the other third were T effector memory (T-EM) cells.

Clonal Expansion. Doughnuts show the T-cell pool in the CSF. While a majority of T cells from healthy controls were unique, i.e. not expanded (white), a majority of T cells in AD CSF had clonally expanded two to four times (orange), five to nine times (blue), or more than 10 times (green). For expanded clones, each colored wedge represents the percentage of total TCRs in the pool. Being too numerous, unique clones (white) are not represented by wedges. [Courtesy of Gate et al., Nature, 2020.]

The researchers also found more clonal expansions in the CSF of six people with PD, including two people with highly expanded clones, than in 10 controls. This suggested the phenomenon is not limited to AD.

The cells did not appear benign. Using single-cell RNA sequencing, the researchers found that the most highly expanded T-cell clones in the CSF expressed a bevy of pro-inflammatory cytokine and cytotoxic proteins, including Granzyme A, also made by CD8+ T cells in AD patients. The findings imply that these CNS T cells were killing cells that waved their specific antigenic flags in the brain, commented Terrence Town of the University of Southern California in Los Angeles. Granzyme A is the smoking gun, Town added.

To which antigens were these clones responding? For most of the clones, this question is unanswered. Employing TCR sequencing with a large helping of computational wizardry, the researchers identified T-cell clones in two people with AD and one with MCI that carried the T-cell receptors recognizing the same antigenan epitope from the EBNA3 protein in Epstein-Barr virus. EBV is a herpes virus known to infect the brain. Using an unbiased machine-learning approach, the researchers also picked up T cells in two other patients that reacted to yet another epitope from EBVthis one came from the EBV trans-activator protein BZLF1. No common expanded TCRs were found among controls.

The presence of the EBV-specific T cells is intriguing, but in no way establishes a link between EBV and AD, wrote Howard Weiner and Dennis Selkoe of Brigham & Womens Hospital in Boston in a joint comment to Alzforum. Weiner and Selkoe previously identified T cells specific for A and -synuclein in the blood of AD and PD patients.

The findings dont implicate EBV in the pathogenesis of AD. However, Gate speculated that stress and inflammation in the diseased brain could trigger reactivation of latent EBV, which could lead to recruitment of EBV-specific T cells and the slaughter of any infected neurons. Alternatively, or perhaps additionally, changes at the blood-brain barrier could let more T cells into the brain, Gate added. Town wondered whether damage to the integrity of the blood-brain barrier in vessels wracked with cerebral amyloid angiopathy could explain how CD8+ T cells gained access to those regions.

Guillaume Dorothe of INSERM in Paris said that the T-cell clones in the CSF could reflect clonal expansion that took place outside the brain. Perhaps the cells were responding to peripheral antigens, and then were unselectively recruited to the CSF of inflamed brain, he said. A direct comparison of T-cell clones in the blood and CSF of the same patients could help clarify this point, he added. Defining whether parenchymal T cells share antigen specificities with the clones patrolling the CSF will also be important, Dorothe noted. Regardless of what drove the cells into the CSF and brain, their presence supports the idea that T cells play some part in the neurodegenerative process, and that targeting them could alter the course of disease, he said. Dorothes previous studies in AD mice suggest that amplifying regulatory T cells, which control immune responses including T-cell immunity, slowed disease progression (Dansokho et al., 2016).

Gate did not test how many of the patients had been infected with EBV, nor directly measure EBV infection in brain samples. In a commentary accompanying the paper, Michael Heneka of the German Center for Neurodegenerative Diseases in Bonn urged caution in interpreting the findings. He noted that more than 95 percent of people are infected by EBV in their lifetime, but a previous study detected EBV DNA in only 6 percent of AD brains (Carbone et al., 2014).

Several studies have tied Alzheimers to various viruses, particularly herpes, though their connection to AD pathophysiology remains controversial (Itzhaki et al., 1997; Jun 2018 news;Jun 2018 news).Jessica Shugart

Here is the original post:
Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain - Alzforum

Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement – BioSpace

Gilead Sciencesis boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases. Gilead, along with two venture capital groups, provided Kyverna Therapeutics with an infusion of $25 million and also struck a collaboration with the fledgling company.

On Monday, Kyverna announced it had closed a $25 million Series A investment from Gilead, Vida Ventures and Westlake Village BioPartners, which will be used to advance the companys platform that combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease. In addition to the cash, Gilead and Kyverna entered into a collaboration and license agreement to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Gilead subsidiary Kite Pharma. Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept. Gilead will be granted an option to continue to develop and potentially commercialize any product that comes from the research.

Under terms of this agreement, Gilead will pay Kyverna $17.5 million in upfront cash. Kyverna could earn an additional $570 million in development and commercialization milestones, depending on how the research goes.

Dominic Borie, chief executive officer of Kyverna, called it one of the most exciting times in the industry when a new modality has the potential to become the backbone of treatment for a variety of severe immune-related diseases. Borie is an immunologist and transplant surgeon who joins Kyverna from Horizon Therapeutics where he served as head of External Research and Development. Prior to Horizon, Borie served in numerous leadership functions within Genentech focused on global clinical development of immunology therapies including two anti-CD20 molecules (rituximab and obinutuzumab) in development for orphan immunology indications. Before that, Borie was with Amgen where he served as Medical Director and Global Development Leader for Inflammation.

In addition to Borie, the Kyverna team includes Jeffrey Greve, who will serve as the companys chief scientific officer. Prior to Kyverna, Greve founded and served as CSO of Delinia, an autoimmune disease company acquired by Celgene in 2017.

As part of the $25 million Series A, Fred Cohen, co-founder and senior managing director of Vida Ventures will serve as chairman of Kyvernas board of directors.

We are just beginning to see the potential for cell therapy and the opportunity to change the course of disease... At Vida, we have a long-standing commitment to advancing cell therapy. We believe the team at Kyverna, under Dominic's stewardship and in partnership with Dr. Greve, the architect of the Kyverna scientific platform, has the ability to develop a new class of therapies for serious autoimmune diseases, Cohen said in a statement.

Go here to read the rest:
Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement - BioSpace

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences – PRNewswire

As part of this financing, Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures will serve as Chairman of the Board. Beth Seidenberg, M.D., Co-Founding Managing Director of Westlake Village BioPartners, Desmond Padhi, B.Sc., Pharm. D., Principal at Westlake Village BioPartners,Brian Kotzin, M.D., Senior Vice President of Nektar Therapeutics, Peter Emtage, Ph.D., Senior Vice President, Global Head of Research, Kite, a Gilead Company, one additional representative from Vida Ventures to be named, and Dominic Borie, M.D., Ph.D., will serve on the Company's the Board of Directors.

"We are just beginning to see the potential for cell therapy and the opportunity to change the course of disease. Dominic's skill as an immunologist and transplant surgeon, coupled with his proven leadership skill as an executive in the biopharmaceutical industry is what we require to embark on our bold vision for Kyverna," said Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures. "At Vida, we have a long-standing commitment to advancing cell therapy. We believe the team at Kyverna, under Dominic's stewardship and in partnership with Dr. Greve, the architect of the Kyverna scientific platform, has the ability to develop a new class of therapies for serious autoimmune diseases."

"This may be one of the most exciting times is our industry where a new modality has the potential to become the backbone of treatment for a variety of severe immune-related diseases," said Dominic Borie, M.D., Ph.D., newly appointed CEO of Kyverna. "This opportunity perfectly unites my experience as a surgeon, academic and drug developer with my passion for finding cures for autoimmune diseases. I am proud to serve as Kyverna's CEO and be a part of this team."

Kyverna also announced that it has entered into a strategic collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Kite, a Gilead Company. Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option, upon the exercise of which Gilead will be solely responsible for further clinical development and commercialization efforts for these programs. Gilead will make to Kyverna an upfront payment of $17.5 million and Kyverna may earn an additional $570 million in development and commercialization milestones. Kyverna will also continue to advance its platform and develop proprietary programs beyond the Gilead collaboration.

"Kyverna's approach combines advanced T cell engineering and synthetic biology technologies to develop significant new therapies for autoimmune and inflammatory diseases," said Beth Seidenberg, M.D., Co-Founding Managing Director of Los Angeles-based Westlake Village BioPartners. "The strategic collaboration with Gilead Sciences in autoimmune diseases enables Kyverna to apply its therapeutic approach to this important unmet need."

Dr. Borie is an accomplished immunologist and digestive tract and liver transplant surgeon with extensive experience in drug development. He joins Kyverna from Horizon Therapeutics where he served as Vice-President and Head, External Research and Development. Prior to Horizon, Dr. Borie served in numerous leadership functions within Genentech focused on global clinical development of immunology therapies including two anti-CD20 molecules (rituximab and obinutuzumab) in development for orphan immunology indications. Dr. Borie had joined Genentech from Amgen where he served as Medical Director and Global Development Leader for Inflammation. He started his career in industry at Roche as Director of Transplantation research before transitioning to Translational Medicine roles for inflammation. Prior to the transition to industry, Dr. Borie was in academia at Stanford University as the Director, Transplantation Immunology Laboratory where he became a key contributor in the validation of JAK inhibition as a new immunomodulatory approach to treating rheumatoid arthritis. Dr. Borie was previously a digestive surgery and liver transplantation attending surgeon at Pitie- Salpetriere Hospital, Assistance Publique in Paris, France. He received his Ph.D. in transplantation immunology from the University of Paris V - Descartes and his M.D., Master's degree in Immunology and Certificate of Immunology and Immunopathology from the University of Paris XII.

About Vida VenturesVida Ventures is a next-generation life sciences investment firm founded by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together they form an independent, bold investment group bound together by a simple word life. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently has approximately $1 billion under management. For more information on Vida Ventures, please visit http://www.vidaventures.com, on LinkedIn or follow on Twitter @Vida_Ventures.

About Westlake Village BioPartnersWestlake Village BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team's unique experience in successfully identifying and developing breakthrough therapies and building organizations. For more information, please visithttp://westlakebio.com/.

About Kyverna TherapeuticsKyverna Therapeutics, located in the San Francisco East Bay, is a cell therapy company engineering a new class of therapies for serious autoimmune diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. For more information, please visit http://kyvernatx.com/.

synNotch is a registered trademark of Kite Pharma, Inc.

SOURCE Kyverna Therapeutics

Homepage

More here:
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences - PRNewswire

Black Country babies at risk as they miss out on vital jabs – expressandstar.com

The British Society for Immunology has urged the government to deliver on its promise to develop the UKs first vaccine strategy to protect communities against nasty diseases.

Young children should get the so-called six-in-one jab, which protects against six serious infections including polio, whooping cough and diphtheria, in the first few months of their lives.

But new Public Health England data shows that the uptake rate for the West Midlands over the period was 92.2 per cent the second-lowest of any region in the country. It compares to one of the best regions, the North East, where 95.4 per cent of children are immunised.

A further breakdown of the figures show that in Wolverhampton, just 89.7 per cent of babies who had their first birthday in the six months to September were vaccinated. It means 173 children missed out, with the area falling way short of the 95 per cent rate recommended by the World Health Organisation to prevent outbreaks.

In Walsall the figure was 93.1 per cent, with 131 children missing out, and in Sandwell it was 90.2 per cent, with 223 children not getting vaccinated. Dudley was one of the best areas, with 96 per cent of one-year-olds having the jabs, and only 75 babies missing out.

Over in Staffordshire it was 94.7 per cent, just shy of the recommended 95 per cent rate. About 224 children missed out on being vaccinated.

Low levels of vaccination coverage matter as it means these diseases have the potential to spread within our communities, infecting unvaccinated people, with young babies and people with compromised immune systems particularly at risk, said Dr Doug Brown of the British Society for Immunology.

We urge the new government to deliver on its promise to develop the UKs first vaccine strategy and to fully fund immunisation services to ensure our communities are protected against these preventable diseases.

But he also urged parents to make sure their children get the jabs, adding: If anyone is worried their child hasnt received all the doses of the six-in-one vaccine, they should make an appointment at their GP surgery. Its much better to get your child vaccinated than put them at risk.

Read the original here:
Black Country babies at risk as they miss out on vital jabs - expressandstar.com

Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products – PRNewswire

DENVER, Jan. 15, 2020 /PRNewswire/ --Artisan Bio, Inc., a stealth cell therapy engineering company, today announced it has entered into a global research and collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") for the discovery, development, and commercialization of novel cell therapy products.

Under the terms of the agreement, Artisan Bio will deploy its STAR platform and synthetic biology expertise to construct customized and precisely engineered cell therapies. Artisan will lead discovery efforts, including gene editing, and Takeda will be responsible for the development, manufacturing, and commercialization of the resulting cell therapy products.

"We are thrilled to collaborate with Takeda and combine our advanced cell engineering capabilities with Takeda's visionary cellular therapy programs," said Ryan T. Gill, CEO of Artisan Bio. "Many limitations that exist in current generation cell therapies can be addressed through the precision engineering of cells for enhanced performance. This collaboration will accelerate the availability of more effective next-generation cellular therapies for patients with high unmet needs."

About Artisan Bio:Artisan's vision is to design, build, and deliver cells and precision engineering processes thatadvance cellular therapies across a broad range of human health indications. The company's designer cell engineering and data analysisSTARplatform enables partners to more rapidly and cost effectively generate safer and more efficacious cell therapies. By engaging in strategic collaborations with innovativepartners, Artisan seeks to deliver customizable cellengineering solutions that meet the complexitiesassociatedwith next-generation cell therapies. Artisan has offices in Denver, Colorado and Copenhagen, Denmark.

For more information, please visithttp://artisancells.com/.

Contact: Tanya Warnecke,info@artisanbio.com

SOURCE Artisan Bio

ArtisanBio

See the original post here:
Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products - PRNewswire

Reflections on the Development of Fascial Tissue: Starting from Embryo | AMEP – Dove Medical Press

Bruno Bordoni, 1, 2 Bruno Morabito 3

1Foundation Don Carlo Gnocchi IRCCS, Department of Cardiology, Institute of Hospitalization and Care with Scientific Address, S Maria Nascente, Milan 20100, Italy; 2Department of Osteopathy, Asomi, Torino, Italy; 3Foundation Polyclinic University A. Gemelli University Cattolica Del Sacro Cuore, Rome, Italy

Correspondence: Bruno Bordoni Tel +39 02 3496300617Email bordonibruno@hotmail.com

Abstract: A great many articles discuss the histological aspects of fascial tissue in detail, but at the same time, there are many contradictions within the literature. In addition, there is a paucity of scientific data that allow straightforward classification of what tissue the fascia truly is. More precise classification of fascial tissue is essential in improving clinical care and effectively framing patient needs. Embryology is an indispensable starting point for understanding the many functions of the fascial tissue. This scientific discipline allows us to observe the relationships and adaptability of fascia both at local and systemic levels. This article reflects on modern scientific knowledge concerning the classification of fascia from an embryological standpoint with the aim of improving our understanding of connective tissue.

Keywords: fascia, myofascial, embryology, anatomy, surgery, fibroblast

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See more here:
Reflections on the Development of Fascial Tissue: Starting from Embryo | AMEP - Dove Medical Press

LETTERS TO THE EDITOR: Investigation is over; on extending grace; representing us well – Northwest Arkansas Democrat-Gazette

Investigation is over

Surprise! The Justice Department's investigation into Hillary Clinton's everything under the sun has finally concluded with a whimper and a big old nothing-burger. What once was a screaming front-page headline for years is now delegated to a quiet inside-page article that tells of her vindication.

Yet, the "Crooked Hillary" characterizations remain a prominent part of President Trump's repertoire at his rallies, as his cult followers continue to mindlessly chant "lock her up," sounding like a frenetic vigilante.

These cult members, the meat and potatoes of Trump's base, seem to have a Hillary chip implanted in their brains, and there it will probably remain, perhaps forever, along with a Barack Obama chip and some Joe and Hunter Biden fragments.

JACK ALBERT

Eureka Springs

On extending grace

December's Voices Letter of the Month comes from William Spilman. Mr. Spilman informs us he is a graduate of a well-respected seminary. He also informs he is more defined by his theological beliefs than political beliefs. I believe these credentials and beliefs are provided as a basis for his defense of the Christianity Today editorial by its editor Mark Galli.

It's appropriate to recognize Christianity Today was founded by Billy Graham, probably the greatest evangelist ever. Mr. Graham advised many presidents of both political parties over the years regarding spiritual matters. Some of those presidents, it was later revealed, embraced and committed immoral acts. Some routinely slandered their former colleagues and opponents with profane and hateful remarks.

Mr. Graham's son and other evangelical leaders now advise our current president. However, in today's political environment, human weakness is used as a tactic in a political strategy to gain advantage. Mr. Spilman believes Franklin Graham and others are guilty of hypocrisy by associating themselves with a man of moral failures. I am reminded of the Jewish leaders who accused Jesus of violating God's law by associating, even dining, with known sinners. I'm certain both Mr. Spilman and Mr. Galli are not sinless. Might they be hypocritical?

Mr. Spilman seems vindicated in his opinion when he points out Mr. Trump admits his immorality and, Spilman says, is proud of it. That I'm not able to know.

Mr. Spilman is concerned Graham and other evangelicals will damage Christian thinking and witness. He believes evangelicals are giving Trump cheap grace. God's grace extended to us all at Calvary was provided for the immoral, the wicked and the evil in all of us. Is it cheap grace to model that to the powerful or even to the weak?

MICHAEL SANDERS

Little Rock

Representing us well

Mr. Franklin Furlough chastised our congressman for not representing his constituents (the ones protesting his support of our president). Well, I feel Congressman Hill continues to represent the views of the majority who voted for him very well!

HAP PETERSON

Hot Springs Village

Protecting the unborn

Sanctity of Human Life Sunday is Jan. 19. We need to pause and consider how abortion devalues this precious gift of life. The taking of the life of an innocent human baby--abortion--is a crime against humanity. How can we or our government officials turn a blind eye to protecting the most vulnerable in our society, even condoning it?

We now know (even as we really did in 1973) that life begins at conception. My college and graduate classes in embryology showed that the "size" of the child (one day or 40 weeks) makes no difference. It doesn't instantly become a human being at "first viability" or when it "takes its first breath" or if the parents "decide to let it live after its birth." It is a distinct person with its own DNA from the moment it was conceived.

And we know that abortion is not "women's health care or rights"--that the baby is a totally separate life from its mother. We know abortion can hurt women both psychologically and physiologically. We know pain can be felt by the baby as early as eight weeks in utero, and there's a measurable heartbeat within two months.

But most importantly, abortion is a terrible sin against our creator God. God has given us a conscience to know right from wrong (culture doesn't give this). Deep down, though some would try to deny it, we know abortion is wrong. Abortion is perhaps the greatest moral sin of our generation.

We need to support those in a position to make a difference and who are definitely pro-life. C.S. Lewis said pain is God's "megaphone to rouse a deaf world." We should be shouting out against the pain and death of unborn babies. Do you hear them?

DON ECKARD

Bentonville

In The Twilight Zone

A friend of mine asked me if I quit writing letters to the editor because he has not seen any lately. I told him that besides having moved and dealing with some health issues, I really didn't know what to write.

It seems that we have crossed over into The Twilight Zone in this country. Nothing makes sense anymore. Up is down, right is wrong, lies and deceit are perfectly acceptable. So is maligning the character of and threatening respectable witnesses who have served our country honorably and testified during the House hearings. We have a president who thinks he can get away with anything because he has so far, thanks to his defenders in Congress and his base.

So instead or worrying and driving myself crazy, I decided to ignore it ... for a while, anyway!

ROSE GOVAR

Maumelle

If he cast a ballot ...

Would Jesus vote for Donald Trump?

HOWARD GARRISON

Hot Springs Village

Editorial on 01/14/2020

Visit link:
LETTERS TO THE EDITOR: Investigation is over; on extending grace; representing us well - Northwest Arkansas Democrat-Gazette